Naltrexone

Overview

Naltrexone is oral opiate receptor antagonist. Naltrexone is derived from thebaine and is extremely similar in structure to oxymorphone. Like parenteral naloxone, Naltrexone is a pure antagonist (i.e., agonist actions are not apparent) but has better oral bioavailability and much longer duration of action than naloxone. Clinically, Naltrexone is used to help maintain an opiate-free state in patients who are known opiate abusers. It was approved by the FDA in 1984, and for the treatment of alcoholism, it was approved in january 17, 1995. Like naloxone, Naltrexone is a competitive antagonist at opiate receptor subtypes µ, , and Like naloxone, Naltrexone is a competitive antagonist at opiate receptor subtypes µ, ? and d. It can either prevent or displace opiate agonists from binding at these receptors. It does not antagonize the effects of non-opiates such as cocaine, ethanol, amphetamines, barbiturates, or benzodiazepines.

Categories

• 4 Antidotes and other substances used in poisonings
  • 4.2 Specific antidotes
  • 4.2.2 Opioid analgesic overdose

Page headings

Primary Characterstics

Indications

Pharmacokinetics

Contraindications

Drug Interactions

Side Effects

Dosage

Cisplatin's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
50 mg	50 (50)	24 hourly	PO	Then.
Paedriatic Dosage (20kg)
				Safety not established
Neonatal Dosage (3kg)
No data regarding the neonatal dosage details of Cisplatin is available.

High Risk Groups

Warning / Precautions

Storage Conditions

Interference in Pathology

Brands / Trade Names of Cisplatin

Manufacturers of Naltrexone in Pakistan

Back to top